Simvastatin

Recruitment for this study, to explore whether simvastatin may be an effective treatment for Parkinson’s is now underway. The study is being directed by Plymouth University Peninsula Schools of Medicine and Dentistry (PUPSMD), and has been supported by the JP Moulton Trust and The Cure Parkinson’s Trust. For further details please see our press release about the trial and you can also listen to Dr Jon Stamford on regional radio discussing it.

The trial is seeking 198 people with Parkinson’s to participate and are involving 21 centres around the country.

Full details of all the Centres involved and how you can find out more is on the PD Stat Study website.

Dr Camille Carroll, chief investigator for the study and consultant neurologist at PUPSMD said, ‘I am very excited about PD STAT. This will be the first study in The Cure Parkinsons’s Trust Linked Clinical Trials Initiative and we are delighted to be able to provide this opportunity for our patients. This study will tell us whether simvastatin has potential as a neuroprotective therapy in Parkinson’s, and will also tell us very valuable information about the best way to design trials like this – which is so important for us to be able to deliver research with the best chance of success.’

If you already take a statin, we would also like to hear from you and would be grateful if you could complete this survey: https://www.surveymonkey.com/s/StatinsPD

RELATED ITEMS

  • Dr David Devos is leading Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s. 'The Cure Parkinson’s Trust…
  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • The quiet revolution I think we all accept the notion that clinical trials are central to the development of new medicines and new treatments for Parkinson's. And it's also true that the majority of these will be conducted by the pharmaceutical industry or academic units. Both have a strong vested…
  • A new study, part of The Cure Parkinson's Trust's Linked Clinical Trials Programme, is starting at University College London Hospital (UCLH). The study is researching a new possible treatment, EPI-589, to explore whether it is well tolerated and could improve the biochemical profile in Parkinson’s patients. The study will involve three months…
  • On the 17th October, the New Scientist reported exciting results from a six month study of twelve patients with Parkinson’s or Lewy Body Dementia taking an expensive cancer drug called nilotinib.  The article announced that scientists at Georgetown University Medical Centre in Washington had seen 'fast improvement' in the volunteers…